期刊
AGING-US
卷 11, 期 18, 页码 7357-7385出版社
IMPACT JOURNALS LLC
DOI: 10.18632/aging.102214
关键词
miR-375-3p; chemoresistance; YAP1; SP1; Hippo-YAP1 signaling pathway
资金
- Key Project of Science and Technology Development of Nanjing Medicine [ZKX18030, ZDX16001]
- National Nature Science Foundation of China [81802093]
- Innovation team of Jiangsu provincial healthstrengthening engineering by science and education [CXTDB2017008]
- Jiangsu Youth Medical Talents Training Project [QNRC2016066, QNRC2016074]
- Jiangsu 333 High-level Talents Cultivating Project [BRA201702]
Clinically, one of the principal factors in the failure of advanced colorectal cancer (CRC) treatment is chemoresistance to 5-fluorouracil (5FU)-based chemotherapy. Although microRNA-375-3p (miR-375) is considered a tumor suppressor in multiple cancers, the mechanism of miR-375 in the regulation of drug resistance in CRC remains unclear. In this study, we investigated the chemosensitivity of miR-375 to 5FU in CRC from biological and clinical aspects. We found that miR-375 was significantly downregulated in CRC tissues and cell lines, and low miR-375 expression was strongly correlated with poor overall survival in CRC patients. Overexpression of miR-375 sensitized CRC cells to a broad spectrum of chemotherapeutic drugs in vitro and in vivo. Further mechanistic analysis demonstrated that miR-375 enhanced CRC cell sensitivity to 5FU by directly targeting YAP1 and SP1. MiR-375 downregulated YAP1, resulting in reduced expression of the Hippo-YAP1 pathway downstream genes CTGF, cyclin D1 and BIRC5 (also known as survivin). Overall, miR-375 was confirmed as a prospective molecular biomarker in the chemoresistance and prognosis of CRC patients, and the synergy between miR-375 and chemotherapeutic drugs could be a promising therapeutic strategy for CRC patients, especially with chemoresistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据